Balyasny Asset Management LLC Rigel Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $4,320 - $76,731	6,448 Added 22.17%	35,534 $53,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $31,994 - $354,849	29,086 New	29,086 $34,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $10,376 - $49,403	-15,487 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $34,381 - $53,430	15,487 New	15,487 $46,000
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $23,030 - $30,514	-11,515 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $23,951 - $38,690	11,515 New	11,515 $26,000
Q2 2018 Aug 14, 2018	SELL	$2.83 - $4.11 $191,166 - $277,630	-67,550 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.54 - $4.54 $239,127 - $306,677	67,550 New	67,550 $239,000
Q4 2017 Feb 14, 2018	SELL	$3.23 - $4.3 $64,923 - $86,430	-20,100 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $43,818 - $51,657	20,100	20,100 $51,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.